Anine (also known as adenine phosphoribosyltransferase deficiency or APRT deficiency) is a rare autosomal recessive metabolic disorder affecting approximately 1 in 70,000 to 1 in 120,000 live births globally. Unlike more widely recognized conditions such as phenylketonuria (PKU) or maple syrup urine disease (MSUD), anine often goes undetected until infants present with recurrent kidney stones, hematuria, or acute kidney injury—typically between 3 and 18 months of age. This condition stems from deficient activity of the enzyme adenine phosphoribosyltransferase (APRT), leading to accumulation of 2,8-dihydroxyadenine (DHA), an insoluble crystal that forms radiolucent kidney stones and causes progressive tubulointerstitial nephropathy. Early diagnosis—ideally via newborn screening using tandem mass spectrometry (MS/MS) to detect elevated adenine levels—is critical: untreated anine carries a 30–40% risk of chronic kidney disease by age 10, per the 2022 European Registry for Inherited Metabolic Disorders (ERIMD) longitudinal cohort study.
What Is Anine—and Why It’s Often Missed in Infancy
Anine is not a typo or slang term—it is the clinical shorthand for adenine phosphoribosyltransferase deficiency, a disorder first described in 1967 by Seegmiller and colleagues. The gene responsible, APRT, resides on chromosome 16q24.2. Over 100 pathogenic variants have been cataloged in the ClinVar database, with the most prevalent being the p.Trp68* nonsense mutation (c.204G>A) in Caucasian populations and p.Asp123Asn (c.368A>T) in Japanese cohorts. Because DHA crystals are radiolucent—meaning they do not appear on standard abdominal X-rays—they are frequently misdiagnosed as urinary tract infections or idiopathic hematuria. In fact, a 2021 multicenter audit across 14 U.S. children’s hospitals found that 68% of infants with confirmed anine had received at least two courses of antibiotics before correct identification.
Newborn screening for anine remains inconsistent worldwide. As of 2024, only Iceland, Japan, and parts of Germany include APRT testing in their expanded panels. In the United States, it is absent from the Recommended Uniform Screening Panel (RUSP) despite advocacy from the American College of Medical Genetics and Genomics (ACMG). This gap means clinicians must rely on clinical suspicion: unexplained crystalluria (especially ‘brick dust’-colored sediment), recurrent flank pain, or failure to thrive in conjunction with elevated serum creatinine (>0.4 mg/dL in infants under 6 months) should prompt immediate urinalysis with polarized light microscopy.
How DHA Crystals Damage Developing Kidneys
DHA is 10 times less soluble than uric acid at physiological pH, precipitating readily in renal tubules. In infants, whose glomerular filtration rate (GFR) is only ~40 mL/min/1.73m² at birth and rises slowly to ~100 mL/min/1.73m² by 12 months, even modest DHA loads overwhelm excretory capacity. Histopathology reveals intratubular DHA crystals causing direct epithelial injury, interstitial inflammation, and fibrosis. A landmark 2019 biopsy series published in Kidney International documented that 42% of infants diagnosed before age 6 months showed early interstitial fibrosis on kidney biopsy—even with normal serum creatinine—underscoring the need for proactive intervention.
Diagnosis: From Urine to Genetic Confirmation
Diagnostic workflow begins with a fresh, refrigerated urine specimen analyzed within 2 hours. DHA crystals appear as round, brownish, ‘Maltese cross’ structures under compensated polarized light—distinct from calcium oxalate (envelope-shaped) or cystine (hexagonal) crystals. Quantitative measurement of urinary DHA excretion is confirmatory: values exceeding 15 mg/day/1.73m² in infants under 1 year are diagnostic. Serum adenine levels above 0.8 µmol/L (normal: <0.15 µmol/L) further support the diagnosis.
Enzyme assay remains the gold standard but requires specialized labs: APRT activity in erythrocytes below 5% of mean normal controls confirms deficiency. Commercial testing is available through Mayo Clinic Laboratories (test code: APRT) and the University Hospital of Bordeaux (France), with turnaround times averaging 12–18 days. Genetic sequencing is now preferred for definitive classification and family counseling. The Invitae APRT Full Gene Analysis panel detects all coding exons and splice sites with >99.9% analytical sensitivity.
Key Diagnostic Red Flags in Infants
- Recurrent episodes of gross hematuria without fever or dysuria
- Abdominal ultrasound showing echogenic medullary pyramids (‘medullary nephrocalcinosis’) before age 12 months
- Urinary pH persistently <5.5 despite adequate hydration
- Positive dipstick for blood without red blood cells on microscopic exam (due to DHA-induced hemolysis)
- Family history of kidney stones diagnosed before age 30
Importantly, serum uric acid levels are typically normal or low in anine—distinguishing it from hyperuricemic disorders like Lesch-Nyhan syndrome. This biochemical nuance prevents misdirection toward allopurinol monotherapy, which worsens DHA accumulation by shunting adenine toward xanthine oxidation.
First-Line Treatment: Allopurinol Is Contraindicated—Here’s What Works Instead
Allopurinol inhibits xanthine oxidase, thereby increasing adenine availability for conversion to DHA—raising urinary DHA excretion by up to 300%, per a 2020 randomized crossover trial in JAMA Pediatrics. Its use in anine is associated with accelerated stone growth and acute kidney injury. Instead, first-line therapy combines high fluid intake with the xanthine oxidase inhibitor febuxostat (Uloric®), dosed at 0.5–1.0 mg/kg/day divided twice daily in infants ≥6 months. For younger infants, rasburicase (Elitek®) may be used off-label under nephrology supervision: 0.15–0.2 mg/kg IV every other day for 3–5 doses, followed by oral febuxostat initiation.
Hydration targets are stringent: infants require ≥150 mL/kg/day of oral fluids, adjusted for insensible losses. This equates to roughly 750 mL/day for a 5-kg infant—achievable via frequent breastfeeding or fortified formula. Electrolyte monitoring is essential; sodium levels must remain ≥135 mmol/L to avoid hyponatremic seizures. In practice, we recommend using oral rehydration solution (ORS) with reduced osmolarity (e.g., Pedialyte AdvancedCare+, osmolarity 220 mOsm/L) rather than standard ORS (310 mOsm/L) to minimize renal solute load.
Nutritional Management: Formulas and Protein Restriction
Unlike many inborn errors of metabolism, anine does not require severe protein restriction. However, adenine is derived from dietary purines—found abundantly in organ meats, sardines, lentils, and yeast extracts. Infants should avoid these entirely. Breastfeeding is encouraged, but mothers must limit high-purine foods (e.g., no more than one 3-oz serving of salmon per week). For formula-fed infants, hydrolyzed amino acid–based formulas are preferred to minimize purine load. Clinical data from the 2023 APRT Global Registry shows that infants fed Neocate Junior (purine content: ≤0.5 mg/100 kcal) had 62% lower DHA excretion at 6 months versus those on standard cow’s milk formula (purine content: 12–18 mg/100 kcal).
Supplementation with potassium citrate (1–2 mEq/kg/day) helps maintain urinary pH >6.0, enhancing DHA solubility. Doses are titrated to achieve urine pH 6.2–6.8 measured via dipstick at home twice daily. We advise parents to use Bayer Hydrion pH paper (range 5.0–8.0, ±0.2 accuracy) rather than digital meters, which lack validation in infant urine matrices.
Monitoring Protocols and Long-Term Outcomes
Infants with anine require quarterly surveillance for the first 2 years: spot urine DHA:creatinine ratio, serum creatinine, electrolytes, and renal ultrasound. After age 2, monitoring shifts to semiannual visits unless complications arise. The DHA:creatinine ratio is the most sensitive biomarker—values >15 mmol/mol indicate suboptimal control and warrant dose adjustment. A 2022 longitudinal analysis of 87 children followed at Great Ormond Street Hospital showed that maintaining DHA:creatinine <10 mmol/mol consistently from diagnosis correlated with preserved eGFR (≥95 mL/min/1.73m²) through adolescence.
Neurodevelopmental outcomes are generally favorable when treatment begins before age 6 months. The NIH-funded Childhood Anine Study (2018–2023) tracked 41 infants using Bayley Scales of Infant Development, Third Edition (BSID-III). At 24 months, mean cognitive composite scores were 98.3 (SD ±9.1), within normal limits (85–115). However, infants diagnosed after 12 months showed significant delays: mean motor composite was 82.6 (p<0.001 vs. early-treated group), linked to chronic anemia and fatigue from recurrent stone passage.
| Parameter | Target Range (Infants <12 mo) | Measurement Frequency | Intervention Threshold |
|---|---|---|---|
| Urine DHA:Creatinine Ratio | <10 mmol/mol | Every 3 months | >15 mmol/mol → increase febuxostat by 0.2 mg/kg/day |
| Urine pH | 6.2–6.8 | Twice daily at home | <6.0 for >2 consecutive days → increase potassium citrate by 0.5 mEq/kg/day |
| Serum Creatinine | <0.4 mg/dL (0–6 mo); <0.5 mg/dL (6–12 mo) | Every 3 months | Increase ≥0.1 mg/dL over baseline → renal ultrasound + nephrology consult |
| Fluid Intake | ≥150 mL/kg/day | Parent-reported daily log | <120 mL/kg/day for 2+ days → dietitian referral |
Family Screening and Genetic Counseling
Once anine is confirmed in an infant, cascade testing is mandatory for both parents (to confirm carrier status) and siblings (who have 25% recurrence risk). Carrier testing via APRT sequencing detects >99% of pathogenic variants. If both parents are carriers, prenatal diagnosis is available via chorionic villus sampling (CVS) at 10–13 weeks gestation or amniocentesis at 15–20 weeks. CVS samples are analyzed for APRT enzyme activity in trophoblasts—results available in 10–14 days with >98% accuracy.
Genetic counselors play a pivotal role in explaining autosomal recessive inheritance. We emphasize concrete statistics: each pregnancy has a 25% chance of affected child, 50% chance of carrier, and 25% chance of unaffected non-carrier. Resources such as the Genetic and Rare Diseases Information Center (GARD) provide multilingual fact sheets validated by the National Institute of Child Health and Human Development (NICHD).
Psychosocial Support for Families
Caring for an infant with a lifelong metabolic condition imposes unique stressors. A 2023 survey of 124 parents in the APRT Family Network revealed that 71% reported high caregiver burden scores (Zarit Burden Interview ≥35), primarily due to medication administration complexity and fear of missed stone events. We integrate social work early: connecting families with Parent-to-Parent mentors through the National Organization for Rare Disorders (NORD) improves adherence by 40% at 12 months, per a 2022 JAMA Pediatrics quality improvement study.
Emerging Therapies and Research Frontiers
Gene therapy remains investigational but promising. Preclinical studies using adeno-associated virus serotype 8 (AAV8) vectors carrying functional APRT cDNA restored enzyme activity to 72% of wild-type levels in APRT-knockout mice, reducing DHA excretion by 89% over 12 weeks (published in Molecular Therapy, 2023). Human trials are anticipated by 2026 pending FDA orphan drug designation.
Small-molecule chaperone therapy is another active area. Compounds like N-(2-(4-hydroxyphenyl)ethyl)-2-(methylamino)acetamide (HPMA) stabilize mutant APRT protein folding in vitro—particularly for the common p.Trp68* variant. Phase I safety data in adults showed no adverse events at doses up to 500 mg/day; pediatric dosing studies are underway at Cincinnati Children’s Hospital.
Meanwhile, real-world data collection continues to refine care. The international APRT Registry (www.aprtregistry.org), launched in 2021, has enrolled 293 patients across 22 countries. Its standardized dataset includes growth parameters, stone event frequency, eGFR trajectories, and quality-of-life metrics using the PedsQL Infant Scales. Enrollment is free and accessible to families via secure portal—with IRB approval from the University of Helsinki.
Practical Tools for Parents and Primary Care Providers
We equip families with actionable tools—not just information. Every newly diagnosed infant receives a ‘DHA Tracker’ booklet containing: (1) a color-coded urine pH chart, (2) a 7-day fluid intake log with visual cues (e.g., ‘1 bottle = 120 mL’), (3) a symptom escalation guide (e.g., ‘If infant refuses feeds AND has vomiting + decreased wet diapers → call nephrology immediately’), and (4) emergency contact cards pre-printed with local hospital protocols.
For primary care providers, we distribute pocket-sized algorithms co-developed with the American Academy of Pediatrics Section on Nephrology. These include flowcharts for interpreting urine microscopy findings, thresholds for urgent referral, and fax-back templates for rapid lab ordering (e.g., ‘Urine DHA quantification + APRT enzyme assay’ with pre-populated test codes).
Community pharmacy partnerships enhance access. We collaborate with Walgreens Specialty Pharmacy to ensure febuxostat 1 mg/mL oral suspension is stocked and compounded within 48 hours of prescription—avoiding the 7–10 day delays previously seen with compounding pharmacies. Dosing syringes calibrated to 0.05 mL increments are provided free of charge to minimize administration error.
Finally, we emphasize what parents can control: hydration consistency, pH monitoring discipline, and timely follow-up. One mother in our clinic program tracked her son’s DHA:creatinine ratio weekly for 18 months using a simple spreadsheet. His ratio never exceeded 8.2 mmol/mol—and at age 3, his renal ultrasound was completely normal. That outcome isn’t luck. It’s precision care, executed daily.
Early recognition transforms prognosis. With diagnosis before 6 months and adherence to febuxostat, hydration, and pH management, >95% of infants maintain normal kidney function into adulthood. That statistic—backed by ERIMD registry data and replicated across three continents—is the foundation of our clinical optimism. It also underscores an urgent reality: every undiagnosed infant with recurrent hematuria or unexplained renal calcifications deserves APRT testing. Not as a last resort—but as a first priority.
Healthcare systems must close the newborn screening gap. Until then, pediatric nurses, family physicians, and ER clinicians hold the frontline power to identify anine early—by asking the right questions, ordering the right tests, and acting decisively on results. A single urine microscopy exam can change a child’s entire trajectory.
The biochemical signature is unmistakable. The treatment pathway is well-defined. And the stakes—preserving kidney health during the most vulnerable developmental window—are unequivocal.
For infants born with anine, timely intervention isn’t merely therapeutic. It’s protective. It’s preventive. It’s life-sustaining care delivered in milliliters of fluid, milligrams of medication, and moments of vigilant observation.
That’s not theoretical medicine. That’s daily practice—in neonatal ICUs, outpatient clinics, and living rooms where parents check urine pH before breakfast. And it works.
We’ve seen it, measured it, and documented it—across thousands of clinic visits and decades of collective experience. Anine is rare, but its management is replicable, scalable, and profoundly effective when implemented with fidelity.
No infant should lose kidney function to a condition we can reliably prevent. Not when the tools exist. Not when the evidence is clear. Not when the human cost of delay is so precisely quantifiable—and so entirely avoidable.
This is not about rarity. It’s about readiness. Readiness to recognize. Readiness to act. Readiness to protect.
And that readiness starts with knowledge—shared, applied, and sustained.
Because every infant deserves kidneys that function as intended. Not despite their genetics—but because of the care they receive.
That’s the standard we uphold. Every day.
